Related Experiment Videos
Rheumatoid vasculitis treated with infliximab
A Egon van der Bijl1, Cornelia F Allaart, Jeroen Van Vugt
1Department of Rheumatology, Leiden University Medical Centre, The Netherlands. a.e.van_der_bijl@lumc.nl
The Journal of Rheumatology
|August 4, 2005
Summary
Rheumatoid vasculitis (RV) patients may benefit from anti-tumor necrosis factor-alpha therapy when standard treatments fail. This approach offers a promising alternative for managing systemic RV, improving patient outcomes.
Area of Science:
- Rheumatology
- Immunology
- Vascular Medicine
Background:
- Rheumatoid vasculitis (RV) is a severe complication of rheumatoid arthritis.
- Systemic vasculitis in RV often requires aggressive treatment strategies.
- Standard immunosuppressive therapies may have limited efficacy or significant side effects.
Observation:
- A case study detailing a patient with rheumatoid vasculitis.
- The patient exhibited a positive clinical response to anti-tumor necrosis factor-alpha (TNF-a) therapy.
- This response was observed despite potential challenges with conventional treatments.
Findings:
- Anti-TNF-a therapy demonstrated significant efficacy in managing systemic rheumatoid vasculitis.
- The patient's condition improved with the introduction of TNF-a antagonists.
- This suggests a crucial role for TNF-a in the pathogenesis of RV.
Implications:
- TNF-a antagonists represent a viable and effective treatment option for systemic RV.
- Consideration of anti-TNF-a therapy is warranted for RV patients refractory to immunosuppressants.
- This therapeutic strategy may be particularly beneficial for patients with contraindications to traditional immunosuppressive drugs.